Please ensure Javascript is enabled for purposes of website accessibility

Waiting on GPC

By Brian Lawler – Updated Nov 14, 2016 at 11:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GPC's marketing partner files a European marketing application for its top drug.

Exciting development-stage drugmaker GPC Biotech (NASDAQ:GPCB) announced yesterday that its marketing partner Pharmion (NASDAQ:PHRM) had filed for approval of its lead cancer-fighting drug in the European Union.

GPC's oral chemotherapeutic drug Satraplatin performed very well in a phase 3 study last year. Therefore, the drug will likely gain regulatory approval in the EU since the medical authorities are already familiar with the class of drugs of which Satraplatin is a part.

EU countries like Germany and France are some of the world's largest markets for pharmaceutical drugs. Nonetheless, even if Satraplatin can achieve EU regulatory approval next year, Pharmion and GPC will still have to wait to negotiate reimbursement of the drug with the governments in each country before meaningful sales will ramp up. Consequently, investors shouldn't expect to see consequential royalties from the drug's sales in the EU until late 2008 or the beginning of 2009 at the earliest.

GPC is already awaiting word from the FDA on Satraplatin in the U.S. The day by which the FDA is expected to make its decision is Aug. 15. An advisory panel meeting of experts is scheduled for July.

GPC is flush with approximately $165 million in cash (at current exchange rates) to support its U.S. sales force build-out if Satraplatin gains regulatory approval.

GPC and Pharmion won't have an easy time competing against Sanofi-Aventis' (NYSE:SNY) Taxotere and other chemotherapeutic agents as a treatment for late-stage prostate cancer. But at least the companies have started the countdown on possible EU marketing approval.

Looking for more Foolish drug stock coverage? Try the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$38.40 (-1.87%) $0.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.